Insmed Incorporated

NasdaqGS:INSM

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Drugstores & Retail Pharmacies

💊 Pharmaceuticals

Location

United States

Market Cap

USD 19.50 B

Share Price

USD 102.68

Avg Daily Volume

2,289,787

Change (1 day)

3.24%

Change (1 year)

58.68%

Change (YTD)

48.73%

Insmed Incorporated EPS (Diluted) for the Trailing 12 Months (TTM) ending March 31, 2025: USD -5.95

Insmed Incorporated EPS (Diluted) is USD -5.95 for the Trailing 12 Months (TTM) ending March 31, 2025, a 13.77% change year over year. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.

Insmed Incorporated EPS (Diluted) for the Trailing 12 Months (TTM) ending March 31, 2024 was USD -5.23, a 22.48% change year over year.
Insmed Incorporated EPS (Diluted) for the Trailing 12 Months (TTM) ending March 31, 2023 was USD -4.27, a 12.96% change year over year.
Insmed Incorporated EPS (Diluted) for the Trailing 12 Months (TTM) ending March 31, 2022 was USD -3.78, a 19.62% change year over year.
Insmed Incorporated EPS (Diluted) for the Trailing 12 Months (TTM) ending March 31, 2021 was USD -3.16, a 12.06% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	EPS (Diluted)	Shares (Diluted, Weighted)	Selling, General, and Administrative Expenses (SG&A)	Research and Development (R&D) Expenses

NasdaqGS: INSM

Insmed Incorporated

CEO	Mr. William H. Lewis J.D., M.B.A.
IPO Date	June 1, 2000
Location	United States
Headquarters	700 US Highway 202/206
Employees	1,271
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Drugstores & Retail Pharmacies 💊 Pharmaceuticals

Description

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.